Core B: Single Cell Protein and RNA Sequencing Core

核心 B:单细胞蛋白质和 RNA 测序核心

基本信息

  • 批准号:
    10334092
  • 负责人:
  • 金额:
    $ 5.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2022-06-02
  • 项目状态:
    已结题

项目摘要

Core B Summary Core B serves all 4 projects in this PPG for all RNA sequencing needs, including bulk and single cell RNA- sequencing (scRNA-Seq), protein sequencing by oligonucleotide-tagged antibodies (Ab-Seq), T- and B-cell receptor sequencing (TCR-Seq and BCR-Seq) and ATAC-Seq. Core B is responsible for all quality controls along the workflow. Core B staff consists of wet lab staff and bioinformaticians. They interact with postdocs, technicians, epidemiologists and PIs from the Human Clinical Cardiovascular and Biostatistics Core (Clinical Core C) and from each of the four projects. Workflows are established for mouse (macrophages, sorted T cells) and human (PBMC) cells. Hashtags and antibodies are fully validated, including thresholding, which improves data quality by eliminating signal from unbound antibody and non-specific antibody binding. The previous version of this core (core E in the 2016 Hedrick PPG) was the first group world-wide to use scRNA- Seq in atherosclerosis research. We established and published guidelines for workflows and quality controls in scRNA-Seq, batch effect, doublet and dead cell removal. Core B provides wet lab and bioinformatics service plus well-developed interfaces with all 4 projects and core C. For Ab-Seq, we validated a 192 oligonucleotide- tagged human antibody panel (Biolegend), run on 10x Genomics 5’, which will be used for Ab-Seq in most of the proposed human studies. For mice, we use the Biolegend 138 mouse antibody panel with 10x Genomics 5’. Using this platform, we have successfully assembled tens of thousands of TCRα and β chain pairs (scTCR- Seq) and BCR heavy and light chain pairs (scBCR-Seq). All 4 projects use core B. The specific aims are: (1) To provide the highest quality scRNA-Seq, scAb-Seq, scATAC-Seq, scTCR-Seq and scBCR-Seq for mouse and human samples, including fully documented and rigorous quality controls, designing and optimizing antibody panels and advice on all bioinformatics issues. (2) To provide the highest quality bulk RNA-Seq and ATAC-Seq for mouse and human samples, including fully documented and rigorous quality controls and support for experimental design and planning. (3) To effectively and seamlessly interface with postdocs, technicians, epidemiologists and PIs from the Clinical Core C and from each of the four projects, including sample shipping, receiving, thawing, data processing, visualization and delivery. To provide these services, we have built a team of wet lab technicians, bioinformaticians and computational biologists. Interfaces with all projects and core C are established and working well.
核心B总结 Core B 服务于该 PPG 中的所有 4 个项目,满足所有 RNA 测序需求,包括批量和单细胞 RNA- 测序 (scRNA-Seq)、寡核苷酸标记抗体蛋白质测序 (Ab-Seq)、T 细胞和 B 细胞 受体测序(TCR-Seq 和 BCR-Seq)和 ATAC-Seq。核心 B 负责所有质量控制 沿着工作流程。核心 B 人员由湿实验室工作人员和生物信息学家组成。他们与博士后互动, 来自人类临床心血管和生物统计学核心(临床 核心 C) 以及四个项目中的每一个。为小鼠(巨噬细胞、分选 T 细胞)和人类(PBMC)细胞。标签和抗体经过充分验证,包括阈值处理, 通过消除未结合抗体和非特异性抗体结合的信号来提高数据质量。这 该核心的先前版本(2016 Hedrick PPG 中的核心 E)是全球第一个使用 scRNA 的组织- 动脉粥样硬化研究中的 Seq。我们制定并发布了工作流程和质量控制指南 scRNA-Seq、批次效应、双联体和死细胞去除。 Core B提供湿实验室和生物信息学服务 加上与所有 4 个项目和核心 C 的完善接口。对于 Ab-Seq,我们验证了 192 个寡核苷酸- 标记的人类抗体面板 (Biolegend),在 10x Genomics 5’ 上运行,将用于大多数情况下的 Ab-Seq 拟议的人体研究。对于小鼠,我们使用 Biolegend 138 小鼠抗体组和 10x Genomics 5’。利用这个平台,我们已经成功组装了数以万计的TCRα和β链对(scTCR- Seq)和 BCR 重链和轻链对 (scBCR-Seq)。所有 4 个项目均使用核心 B。具体目标是:(1) 为小鼠提供最高质量的scRNA-Seq、scAb-Seq、scATAC-Seq、scTCR-Seq和scBCR-Seq 和人体样本,包括完整记录和严格的质量控制、设计和优化 抗体小组和有关所有生物信息学问题的建议。 (2) 提供最高质量的bulk RNA-Seq和 适用于小鼠和人类样本的 ATAC-Seq,包括完整记录和严格的质量控制以及 支持实验设计和规划。 (3) 与博士后有效、无缝对接, 来自临床核心 C 和四个项目中每一个项目的技术人员、流行病学家和 PI,包括 样品运输、接收、解冻、数据处理、可视化和交付。为了提供这些服务,我们 建立了一支由湿实验室技术人员、生物信息学家和计算生物学家组成的团队。与所有接口 项目和核心 C 已建立并运行良好。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Klaus F. Ley其他文献

Binding of function‐blocking mAbs to mouse and human P‐selectin glycoprotein ligand‐1 peptides with and without tyrosine sulfation
功能阻断单克隆抗体与小鼠和人 P-选择素糖蛋白配体 1 肽(有或没有酪氨酸硫酸化)的结合
  • DOI:
  • 发表时间:
    2002
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Aravinda Thatte;S. Ficarro;K. Snapp;M. Wild;D. Vestweber;D. Hunt;Klaus F. Ley
  • 通讯作者:
    Klaus F. Ley
Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) correlate with severity of ileitis in experimental Crohn's disease: A novel marker of small intestinal inflammation
  • DOI:
    10.1016/s0016-5085(00)85325-1
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jesus Rivera-Nieves;R. Cartland Burns;Christopher A. Moskaluk;Theresa T. Pizarro;Klaus F. Ley;Fabio Cominelli
  • 通讯作者:
    Fabio Cominelli
α<sub>4</sub>β<sub>1</sub>integrin (VLA-4) blockade reduces neointimal growth after carotid air desiccation injury in the ApoE (−/−) mouse
  • DOI:
    10.1016/s0735-1097(02)80085-7
  • 发表时间:
    2002-03-06
  • 期刊:
  • 影响因子:
  • 作者:
    Kurt G. Barringhaus;J.William Phillips;John M. Sanders;Ann C. Czamik;Klaus F. Ley;Ian J. Sarembock
  • 通讯作者:
    Ian J. Sarembock

Klaus F. Ley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Klaus F. Ley', 18)}}的其他基金

Mechanism of kindlin-3-dependent integrin activation
kindlin-3依赖性整合素激活机制
  • 批准号:
    10676897
  • 财政年份:
    2020
  • 资助金额:
    $ 5.35万
  • 项目类别:
Mechanism of kindlin-3-dependent integrin activation
kindlin-3依赖性整合素激活机制
  • 批准号:
    10229369
  • 财政年份:
    2020
  • 资助金额:
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10112954
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10369710
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    9895858
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10623034
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10565907
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
  • 项目类别:
Core E: Cell sorting, CyTOF and RNA-Seq
核心 E:细胞分选、CyTOF 和 RNA-Seq
  • 批准号:
    10188604
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
  • 项目类别:
Super-resolution confocal microscope
超分辨率共焦显微镜
  • 批准号:
    9274885
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
  • 项目类别:
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosis
项目4:APOB特异性CD4和CD8 T细胞加剧动脉粥样硬化
  • 批准号:
    10334097
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 5.35万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了